| |
All patients
|
Anti-PAD4-negative (P0)
|
Anti-PAD4 only (P4)
|
Anti-PAD4/PAD3 (XR)
|
P value
|
|---|
|
Demographic and RA-related variable
|
(N = 192)
|
(N = 146)
|
(N = 26)
|
(N = 20)
|
P4 vs P0
|
XR vs P0
|
XR vs P4
|
|---|
|
Age (years), mean (SD)
|
55 (12.2)
|
54 (12.1)
|
55 (13.9)
|
59 (8.6)
|
0.755
|
0.077
|
0.288
|
|
Female, %
|
86
|
85
|
96
|
80
|
0.207
|
0.523
|
0.151
|
|
Disease duration (years), mean (SD)
|
8.1 (10.8)
|
7.2 (10.5)
|
10.4 (11.2)
|
12.8 (11.6)
|
0.029
|
0.004
|
0.386
|
|
+anti-CCP, %
|
73
|
67
|
88
|
95
|
0.035
|
0.008
|
0.622
|
|
Total radiographic score,a median (IQR)
|
2 (0–57)
|
2 (0–11)
|
2 (1–104)
|
76 (3–117)
|
0.231
|
0.001
|
0.082
|
|
CRP (mg/dl)
|
14 (36)
|
16 (40)
|
8 (10)
|
9 (13)
|
1.000
|
0.391
|
0.598
|
|
Smoking, %
| | | | |
0.387
|
0.183
|
0.852
|
|
Current
|
56
|
33
|
19
|
15
| | | |
|
Former
|
45
|
21
|
27
|
35
| | | |
|
Never
|
92
|
46
|
54
|
50
| | | |
|
Medications, %
|
|
Methotrexate
|
63
|
63
|
69
|
85
|
0.660
|
0.080
|
0.302
|
|
HCQ
|
29
|
29
|
34
|
20
|
0.645
|
0.441
|
0.336
|
|
Sulfasalazine
|
8
|
8
|
8
|
5
|
1.000
|
1.000
|
1.000
|
|
Leflunomide
|
5
|
5
|
0
|
5
|
0.600
|
1.000
|
0.435
|
|
Infliximab
|
4
|
4
|
0
|
10
|
0.593
|
0.248
|
0.184
|
|
Etanercept
|
4
|
4
|
4
|
10
|
1.000
|
0.248
|
0.572
|
- Categorical variables were tested using Fisher’s exact tests, and continuous variables were tested using Wilcoxon rank sum tests
-
aTotal joint erosion and joint space narrowing
-
CLEAR Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis, RA rheumatoid arthritis, PAD peptidyl arginine deiminase enzyme, CRP C-reactive protein, HCQ hydroxychloroquine, IQR interquartile range
-
P values less than 0.05 are shown in bold
